Literature DB >> 23908331

Myocardial conditioning: opportunities for clinical translation.

Michel Ovize1, Hélène Thibault, Karin Przyklenk.   

Abstract

Myocardial conditioning is an endogenous cardioprotective phenomenon that profoundly limits infarct size in experimental models. The current challenge is to translate this paradigm from the laboratory to the clinic. Accordingly, our goal in this review is to provide a critical summary of the progress toward, opportunities for, and caveats to, the successful clinical translation of postconditioning and remote conditioning, the 2 conditioning strategies considered to have the broadest applicability for real-world patient care. In the majority of phase II studies published to date, postconditioning evoked a ≈35% reduction of infarct size in ST-segment-elevation myocardial infarction patients. Essential criteria for the successful implementation of postconditioning include the appropriate choice of patients (ie, those with large risk regions and negligible collateral flow), timely application of the postconditioning stimulus (immediately on reperfusion), together with proper choice of end points (infarct size, with concomitant assessment of risk region). Remote conditioning has been applied in planned ischemic events (including cardiac surgery and elective percutaneous coronary intervention) and in ST-segment-elevation myocardial infarction patients during hospital transport. Controversies with regard to efficacy have emerged, particularly among surgical trials. These disparate outcomes in all likelihood reflect the remarkable heterogeneity within and among studies, together with a deficit in our understanding of the impact of these variations on the infarct-sparing effect of remote conditioning. Ongoing phase III trials will provide critical insight into the future role of postconditioning and remote conditioning as clinically relevant cardioprotective strategies.

Entities:  

Keywords:  ischemic postconditioning; myocardial infarction; myocardial ischemia; remote conditioning; reperfusion

Mesh:

Year:  2013        PMID: 23908331     DOI: 10.1161/CIRCRESAHA.113.300764

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  35 in total

Review 1.  Current Modalities and Mechanisms Underlying Cardioprotection by Ischemic Conditioning.

Authors:  John H Rosenberg; John H Werner; Michael J Moulton; Devendra K Agrawal
Journal:  J Cardiovasc Transl Res       Date:  2018-05-24       Impact factor: 4.132

Review 2.  Ischaemic conditioning: pitfalls on the path to clinical translation.

Authors:  Karin Przyklenk
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

Review 3.  Cardioprotection by remote ischemic conditioning: Mechanisms and clinical evidences.

Authors:  Alberto Aimo; Chiara Borrelli; Alberto Giannoni; Luigi Emilio Pastormerlo; Andrea Barison; Gianluca Mirizzi; Michele Emdin; Claudio Passino
Journal:  World J Cardiol       Date:  2015-10-26

Review 4.  Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon.

Authors:  Victor Soukoulis; William E Boden; Sidney C Smith; Patrick T O'Gara
Journal:  Circ Res       Date:  2014-06-06       Impact factor: 17.367

Review 5.  Ischemia/Reperfusion.

Authors:  Theodore Kalogeris; Christopher P Baines; Maike Krenz; Ronald J Korthuis
Journal:  Compr Physiol       Date:  2016-12-06       Impact factor: 9.090

6.  Celastrol protects ischaemic myocardium through a heat shock response with up-regulation of haeme oxygenase-1.

Authors:  S Der Sarkissian; J-F Cailhier; M Borie; L-M Stevens; L Gaboury; S Mansour; P Hamet; N Noiseux
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

Review 7.  Opioid receptors and cardioprotection - 'opioidergic conditioning' of the heart.

Authors:  John P Headrick; Louise E See Hoe; Eugene F Du Toit; Jason N Peart
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

8.  From ischemic conditioning to 'hyperconditioning': clinical phenomenon and basic science opportunity.

Authors:  Peter Whittaker; Karin Przyklenk
Journal:  Dose Response       Date:  2014-10-20       Impact factor: 2.658

9.  microRNA-144: the 'what' and 'how' of remote ischemic conditioning?

Authors:  Karin Przyklenk
Journal:  Basic Res Cardiol       Date:  2014-07-31       Impact factor: 17.165

10.  Mitochondrially targeted nitro-linoleate: a new tool for the study of cardioprotection.

Authors:  Sergiy M Nadtochiy; Jerry Madukwe; Fred Hagen; Paul S Brookes
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.